Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Guanfacine Hydrochloride + Psychostimulants in Adult ADHD
NCT02141113Phase 4Completed
- Sponsor
- Rochester Center for Behavioral Medicine
- Start
- Nov 2012
- Primary completion
- Sep 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of guanfacine in attention deficit hyperactivity disorder (ADHD) (2 arms), sponsored by Rochester Center for Behavioral Medicine. Primary endpoint: ADHD-RS Change From Baseline to Endpoint at 8 weeks. Started Nov 2012; status: completed.
02
Drugs
guanfacine
03
Conditions
attention deficit hyperactivity disorder (ADHD)
Beyond the preview
Go deeper on NCT02141113.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02141113.